Prosecution Insights
Last updated: May 29, 2026

Examiner: CONSTANTINE, CHARLES Z

Tech Center 1600 • Art Units: 1651 1657

This examiner grants 58% of resolved cases

Performance Statistics

58.4%
Allow Rate
-1.6% vs TC avg
444
Total Applications
+49.3%
Interview Lift
1136
Avg Prosecution Days
Based on 421 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
9.2%
§102 Novelty
50.3%
§103 Obviousness
12.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18255943 NOVEL SCHIZOCHYTRIUM SP. STRAIN AND POLYUNSATURATED FATTY ACID PRODUCTION METHOD USING SAME Final Rejection CJ CHEILJEDANG CORPORATION
18070870 COATINGS CONTAINING ENZYME FOR STABLE SELF-CLEANING OF ORGANIC STAINS Final Rejection Regents of the University of Minnesota
18544879 GLUCOSYL STEVIA COMPOSITION Non-Final OA PURECIRCLE SDN BHD
18142850 GLUCOSYL STEVIA COMPOSITION Final Rejection PURECIRCLE SDN BHD
18578946 Phytase Variants Non-Final OA AB Enzymes Oy
18576341 PREPARATION METHOD FOR AND APPLICATION OF IMMOBILIZED CELLS FOR MANNOSE PRODUCTION Non-Final OA Tianjin Yeahe Biotechnology Co., Ltd
18269694 ATP-PRT VARIANT WITH REDUCED FEEDBACK INHIBITION BY HISTIDINE, AND HISTIDINE-PRODUCING STRAIN EXPRESSING SAME Final Rejection DAESANG CORPORATION
18320182 System and Method for Liquid Culture of Anaerobic or Microaerophilic Microorganisms Non-Final OA NEOGEN FOOD SAFETY US HOLDCO CORPORATION
18135614 METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES Non-Final OA OPTIMVIA, LLC
17874805 Universal Calibration Method for Assaying Enzymatic Inhibitors Final Rejection Diagnostica Stago
16368330 METHODS AND PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE Final Rejection Okogen, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month